Auris Medical skyrockets 480% after announcing lab-test results that show its nasal spray could protect against Covid-19

• Auris Medical soared as high as 480% on Tuesday on news that its nasal spray, AM-301, could potentially protect against the coronavirus.
• The clinical stage company tested its spray on human nasal cells in a lab, and found that cells treated with AM-301 right before inoculation of the coronavirus saw effective protection.
• In cells treated with the spray, the amount of coronavirus was 90% lower than control groups 48 hours after infection.
• Watch Auris Medical trade live here.

Auris Medical soared as high as 480% on Tuesday after it announced lab-test results that show its nasal spray could protect against the coronavirus. Shares of the Bermuda-based clinical stage company are now trading at over $5 per share, after closing at just $1.1 on Monday.

Auris tested its nasal spray, AM-301, on human nasal cells reconstituted in a lab. Auris found that cultures treated with AM-301 right before inoculation with the coronavirus saw effective protection against the virus.

 48-hours post-infection, the amount of the virus was 90% lower than those observed in controls. 72 hours post-infection, the virus was 99.2% lower. In saline-treated control cultures, the coronavirus replicated efficiently.

Read more:HSBC says buy these 31 global stocks that are exposed to the pandemic's biggest tech disruptions and set to become growth engines of the future

"With our newly developed spray formulation, we have direct evidence that AM-301 has the potential to significantly mitigate the risk of infection of nasal mucosal cells," said Auris Medical CEO Thomas Meyer. 

Meyer said that Auris Meyer will take AM-301 through additional tests and looks to submit to regulatory applications in 2021. 

AM-301 is a drug free nasal spray being developed by Auris' affiliate, Altamira Medica.